Tyrosine kinase inhibitors may boost cardiac risk in chronic myeloid leukemia
Patients with chronic myeloid leukemia (CML) who received tyrosine kinase inhibitors (TKIs) had 1.7 times the rate of arterial or venous vascular events of population-based controls in a large...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Family Practices | Leukemia | Primary Care